Illumina, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4523271090
USD
128.03
0.48 (0.38%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Illumina, Inc. stock-summary
stock-summary
Illumina, Inc.
Pharmaceuticals & Biotechnology
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.
Company Coordinates stock-summary
Company Details
5200 Illumina Way , SAN DIEGO CA : 92122-4616
stock-summary
Tel: 1 858 20245001 858 8822172
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 168 Schemes (59.87%)

Foreign Institutions

Held by 447 Foreign Institutions (32.59%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Jay Flatley
Executive Chairman of the Board
Mr. Francis deSouza
President, Chief Executive Officer, Director
Mr. John Thompson
Lead Independent Director
Prof. Frances Arnold
Independent Director
Ms. Caroline Dorsa
Independent Director
Dr. Robert Epstein
Independent Director
Dr. Scott Gottlieb
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,057 Million
(Quarterly Results - Jun 2025)
Net Profit:
235 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 18,919 Million (Small Cap)

stock-summary
P/E

26.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.41

stock-summary
Return on Equity

43.88%

stock-summary
Price to Book

8.38